Clinical Trial Update: CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update for canagliflozin vs placebo in post-bariatric patients with persistent type 2 diabetes; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Diabetes Mellitus, Type 2, Obesity | Phase 4 | Status: TERMINATED | Results posted: 2020-06-30